Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338414 | 0.93 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL6710733 | 0.92 | MEN1 (0.45) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7477616 | 0.91 | MEN1 (0.44) | MEN1KMT2A | |
| SCHEMBL6632757 | 0.86 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL6631513 | 0.85 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL6633221 | 0.84 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL6659933 | 0.82 | KCNH2 (0.46) | MEN1KMT2A | |
| SCHEMBL6337511 | 0.79 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL6633072 | 0.79 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL6662970 | 0.78 | KCNH2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421089-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | Pharmacia & Upjohn Company (US) | 2004-05-26 | — | — | EP | claimed |
| US-6620810-B2 | Treating a herpesvirus infection, atherosclerosis or restenosis | PHARMACIA & UPJOHN COMPANY | 2003-09-16 | — | — | US | claimed |
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | claimed |
| WO-2003020729-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| EP-1421089-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | Pharmacia & Upjohn Company (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6620810-B2 | Treating a herpesvirus infection, atherosclerosis or restenosis | PHARMACIA & UPJOHN COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2003020729-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IRAK4, IFNAR1 | MEN1 3806/4885KMT2A 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.